Recombinant Human KLK1 Protein
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog No: bt-221413
Formulation: Lyophilized from a solution containing 1xPBS.
Source: Pichia Pastoris.
|Product Name||Recombinant Human KLK1 Protein|
|Bioactivity||Human Kallikrein-1 active Unit Definitin 1 unit will hydrolyze 1 µmole of H-D-Val-Leu-Arg-pNA(S-2266) per minute at pH 8.0 at 37°C Human Kallikrein-1 measured biological activity of no less than 5 Units/mg (S2266 method).|
|Formulation||Lyophilized from a solution containing 1xPBS.|
|Host Species||Homo sapiens (Human)|
|Product Background||Kallikreins are serine protease enzymes having various physiological functions. Kallikreins are implicated in carcinogenesis and have potenital as novel cancer disease biomarkers. KLK1 is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. KLK1 is functionally conserved in its ability to release the vasoactive peptide, Lys-bradykinin, from low molecular weight kininogen. Human Kallikrein-1, also called as Kallidinogenase, Kininogenase or Kininogenin, is an active protein enzyme present in saliva, pancreatic juices, and urine that catalyzes the proteolysis of bradykininogen to bradykinin. Kallikrein-1, which derived from human or porcine, have been used as drugs for a long time, they are mainly used in the treatment f light to medium hypertension and occlusion of cerebral and surrounding blood vessels. KLK1 demonstrates both trypsin- and chymotrypsin-like selectivities with Tyr/Arg preferred at site P1, Ser/Arg strongly preferred at P1', and Phe/Leu at P2. rs5517 in the KLK1 gene is considerably connected with hypertension in a Chinese Han population. KLK1 is expressed de novo in endothelial cells and mediates relaxation of human umbilical veins. The K allele of KLK1 promoter and TT genotype of TGF-beta1 are a genetic KLK1 -130 GN and -128 G-C, and the defenselessness factor contributing to progressive renal descent in Taiwanese primary vesicoureteric reflux children. Induction of KLK1 in carotid arteriosclerosis doesn’t lead to kallikrein-kinins pathway activation. Transgenic rats expressing KLK1 have impaired renal response to acute volume expansion Endothelial cells synthesize and release active form of KLK1on the surface which is important function in maintenance of circulation homeostasis. KLK1 participates in epidermal desquamation through cleavage of desmoglein 1 and regulation by lympho-epithelial Kazal-type-related inhibitor (LEKTI).|
|Product Memo||KLK1 Human Kallikrein-1 Human Recombinant|
|Product Type||Recombinant Protein|
|Purity||>98% as determined by both RP-HPLC and SDS-PAGE|
|Reconstitution||It is recommended to reconstitute the lyophilized KLK1 in sterile 18M-cm H2O not less than 100 µg/ml or more than 10 mg/ml solutions|
|Stability||Recombinant protein is stable up to 1 year at -80℃|
|Storage||Lyophilized KLK1 although stable at room temperature for up to 3 weeks, should be stored under sterile conditions at -20°C. Upon reconstitution KLK1 should be stored at 4°C between 2-7 days and for future use below -20°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid repeated freeze-thaw cycles.|
|Synonym||KLK1, KLK-1, HK1, HK-1, KLKR, KLK6, Tissue Kallikrein, hKLK1, EC 188.8.131.52, Kidney/pancreas/salivary gland kallikrein, Kallikrein-1|
|Usage||Our recombinant proteins are For Research Use Only. This product is not intended or approved for human, diagnostics or veterinary use|
|Last Modified||Mar 08 2019|